Registration Options

Activity Dates: 11/04/2021 - 12/31/2023

Your credit card is charged at time of purchase.

Target Audience

The Psychiatric Pharmacotherapy Review Book is designed for three primary audiences:

  1. It serves as a preparatory book for pharmacists preparing to sit for the BCPP examination.
  2. It offers a review of current evidence-based pharmacotherapy for psychiatric and neurologic conditions for BCPP certified pharmacists seeking BCPP recertification credit (purchase here).
  3. It serves as an educational tool for other healthcare providers on current evidence-based pharmacotherapy for psychiatric and neurologic conditions.

NOTE: The Psychiatric Pharmacotherapy Review Book is a two-year product released at the start of even years (2022, 2024, 2026...).

Session Summary

The Psychiatric Pharmacotherapy Review Book is designed for use by individuals preparing to sit for the Board Certified Psychiatric Pharmacist (BCPP) examination. CPNP surveys show that at least 90% of successful BCPP candidates purchase the Review Book as their primary study tool. One hundred percent of survey respondents indicate that the Review Book was their primary study resource and a key tool to their certification success.

The Book Contains:

  • Comprehensive outlines, written as individual chapters, of the most common psychiatric and neurologic conditions tested for in the BCPP exam.
  • Consistently formatted chapters that include objectives, thorough content, comprehensive reference listings, and self-assessment questions with answer justifications.
  • An e-book version of the book hosted VitalSource Bookshelf, a leading e-textbook solution. This e-book version allows you to take electronic notes as well as download the book to your desktop or mobile device for off line access.

Faculty Information and Disclosures

Charles F. Caley, PharmD, BCPP
Clinical Professor  |  Chair
Western New England University
Springfield, MA

No Relevant Financial Relationships to Disclose

Ryan M. Carnahan, PharmD, BCPP, MS
Associate Professor
University of Iowa, College of Public Health, Epidemiology
Iowa City, IA

Affiliation/Financial interest: Ownership stake in Carnahan Counseling. (My wife is a provider of psychotherapy services and owns this business.
Psychotherapy may be addressed at some point in the chapter)

Jeremy Daniel, PharmD, BCPP, BCPS
Associate Professor of Pharmacy Practice
South Dakota State University College of Pharmacy and Allied Health Professions
Sioux Falls, SD

No Relevant Financial Relationships to Disclose

Sarah E. Grady, PharmD, BCPP, BCPS
Clinical Professor
Drake University
Des Moines, IA

No Relevant Financial Relationships to Disclose

My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: buspirone, lithium, thyroid hormone

Robin N. Hieber, PharmD, BCPP
Clinical Pharmacy Specialist - Mental Health & Clinical Pharmacy Lead
VISN 23 Clinical Resource Hub
Antioch, IL

No Relevant Financial Relationships to Disclose

Megan Maroney, PharmD, BCPP
Clinical Associate Professor
Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey
Long Branch, NJ

Consultant: Novus Medical Education, Pharmacy Times Health-Systems Edition
Speaker's Bureau: Otsuka Pharmaceuticals
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: cabergoline, carbidopa/levodopa,
clonazepam, dextroamphetamine, diphenhydramine, gabapentin, melatonin, oxycodone, methadone, trazodone, venlafaxine

Lindsey N. Miller, PharmD, BCPP
Clinical Pharmacist and Associate Professor
Lipscomb University and Vanderbilt Psychiatric Hospital
Nashville, TN

Speaker's Bureau: Pharmacist Times (sponsor projects I've worked on)
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Personality Disorders: Mood stabilizers,
stimulants, SSRIs, Second/First Generation Antipsychotics, benzodiazepines; Specific SGA medications: aripiprazole, olanzapine, ziprasidone, clozapine, quetiapine;
Specific mood stabilizers: topiramate, lamotrigine, valproic acid

Sandra Mullen, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry
VCU Health Systems
Richmond, VA

No Relevant Financial Relationships to Disclose

My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Off-label use of stimulants, antipsychotics,
alpha-agonists, and mood stabilizers in children and adolescents.

Carol A. Ott, PharmD, BCPP
Clinical Professor of Pharmacy Practice
Purdue University/Eskenazi Health
Indianapolis, IN

Consultant: IU School of Medicine, Department of Psychiatry/Indiana Department of Child Services, IUSM Project ECHO,Lexi Comp/Wolters-Kiuwer, CMS/HHS/Mathematica
Grant/Research: SAMHSA, NACDS, Community Pharmacy Foundation, National Institute  of Food & Agriculture

Chris Paxos, PharmD, BCPP, BCPS, BCGP
Associate Professor of Pharmacy Practice
Northeast Ohio Medical University
Rootstown, OH

No Relevant Financial Relationships to Disclose

Kimberly B. Tallian, PharmD, BCPP, FASHP, FCCP
Advanced Practice Pharmacist - Psychiatry
Scripps Mercy Hospital, San Diego, CA
San Diego, CA

Speaker's Bureau: San Diego Regional Center (probono work)

Michele D. Thomas, PharmD, BCPP
Director of Pharmacy
Springfield Hospital Center
Sykesville, MD

No Relevant Financial Relationships to Disclose

Erika Titus-Lay, PharmD, BCPP, BCPS
Assistant Professor
California Northstate University College of Pharmacy
Elk Grove, CA

No Relevant Financial Relationships to Disclose

Andrew M. Williams, PharmD, BCPP, BCGP
Senior Clinical Pharmacist, Behavioral Health and Neighborhood Pharmacies
Riverside University Health System
Riverside, CA

Consultant: Otsuka Pharmaceuticals
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Cholinesterase inhibitors for all types
of dementia; Antipsychotics, antidepressants, and mood stabilizers for behavioral and psychological symptoms of dementia

 

 

 

Learning Objectives

Topic

 

 

 

Disclosures